Description
Clinical Evidence
• In the STEP clinical trial series, GLP-1(S) was associated with an average weight reduction of up to 15% of body weight over 68 weeks in obese individuals without diabetes.
• The SUSTAIN trials demonstrated significant A1C reductions and improved glycemic control in type 2 diabetic patients.
• In a cardiovascular outcomes study (SUSTAIN-6), GLP-1(S) reduced the risk of major adverse cardiovascular events by 26% compared to placebo.
Potential Side Effects
While generally well-tolerated, potential side effects may include:
• Nausea and vomiting
• Diarrhea or constipation
• Headache
• Fatigue
• Injection site reactions
• In rare cases: pancreatitis or gallbladder-related issues
Note: Side effects often decrease with continued use as the body adjusts.
Disclaimer
This product is intended for research purposes only. It is not approved for human or veterinary use. The information provided is for educational purposes and should not be used as medical advice. Always handle peptides with appropriate safety measures in a licensed laboratory setting.
Reviews
There are no reviews yet.